US2016030321A1PendingUtilityA1

Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions

58
Individually held — no corporate assignee on recordPriority: Jan 16, 2009Filed: Jul 8, 2015Published: Feb 4, 2016
Est. expiryJan 16, 2029(~2.5 yrs left)· nominal 20-yr term from priority
Inventors:Frank Dreher
A61Q 19/02A61K 31/6615A61K 8/55A61K 2800/88A61K 2121/00A61P 17/00A61K 8/066
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for treating or ameliorating at least one symptom of a skin pigmentation disorder or condition comprising at least one calcium sequestering or calcium binding agent. 
     
     
         2 . The composition of  claim 1 , wherein the at least one calcium sequestering or calcium binding agent is a phosphate free of calcium. 
     
     
         3 . The composition of  claim 2 , wherein the phosphate is glycerophosphoric acid or a non-calcium salt thereof. 
     
     
         4 . The composition of  claim 3 , wherein the phosphate is sodium glycerophosphate. 
     
     
         5 . The composition of  claim 1 , wherein the at least one calcium sequestering or calcium binding agent is present in an amount of about 0.1% to about 25% by weight. 
     
     
         6 . The composition of  claim 2 , wherein the phosphate free of calcium is present in an amount of about 1% to about 5% by weight. 
     
     
         7 . The composition of  claim 1 , wherein the composition further comprises at least one additional agent that modulates or regulates at least one step of melanogenesis. 
     
     
         8 . The composition of  claim 7 , wherein the at least one additional agent is selected from the group consisting of L-alanine, glycine, L-isoleucine, L-leucine, hydroquinone, 4-(1-phenylethyl) 1,3-benzenediol, arbutin, bearberry leaf extract, kojic acid, oxyresveratrol, gnetol, a melanosome transfer inhibitor, and an α-MSH antagonist. 
     
     
         9 . The composition of  claim 1 , wherein the composition further comprises at least one skin moisturization and skin rejuvenation agent. 
     
     
         10 . The composition of  claim 9 , wherein the skin moisturization and skin rejuvenation agent is selected from the group consisting of ascorbic acid, vitamin E, jojoba oil, shea butter, human fibroblast lysate, retinoic acid, retinol, and any derivatives thereof. 
     
     
         11 . The composition of  claim 1 , wherein said composition is suitable for topical administration to a subject in need thereof. 
     
     
         12 . The composition of  claim 1 , wherein said composition is in the form of a solution, an oil-in-water emulsion, a water-in-oil emulsion, a gel, an ointment, a patch, a paste, a liquid, a foam, a mousse, a spray, an aerosol, a triple emulsion, a nanoemulsion, a microemulsion, a hydrogel, a jelly, a dispersion, a suspension, and a tape. 
     
     
         13 . The composition of  claim 1 , wherein said composition is substantially free of calcium. 
     
     
         14 . The composition of  claim 1 , wherein said composition is stable, does not cause an acnegenic or comedogenic response, and produces minimal skin irritation in said subject. 
     
     
         15 . A method of treating or ameliorating a skin pigmentation disorder comprising administering an effective amount of the composition of  claim 1  to a patient suffering therefrom. 
     
     
         16 . The method of  claim 15 , wherein the skin pigmentation disorder is selected from the group consisting of melasma, post-inflammatory hyper-pigmentation, pigmentation changes due to skin aging, age or liver spots, freckles, hypo-pigmentation, and hyper-pigmentation. 
     
     
         17 . The method of  claim 15 , wherein the patient is a human. 
     
     
         18 . The method of  claim 15 , wherein the composition is administered to the patient topically. 
     
     
         19 . The method of  claim 15 , wherein, following administration, the composition reduced skin pigmentation in the patient. 
     
     
         20 . A pharmaceutical formulation comprising the composition of  claim 1  and at least one pharmaceutically acceptable carrier. 
     
     
         21 - 32 . (canceled)

Join the waitlist — get patent alerts

Track US2016030321A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.